Open AccessAdult Brainstem Gliomas
Author(s) -
ReyesBotero German,
Mokhtari Karima,
MartinDuverneuil Nadine,
Delattre JeanYves,
LaigleDonadey Florence
Publication year - 2012
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2011-0335
Subject(s) - medicine , temozolomide , brainstem , radiation therapy , glioma , radiology , magnetic resonance imaging , neuroradiology , biopsy , stereotactic biopsy , radiological weapon , neurology , cancer research , psychiatry
Learning Objectives After completing this course, the reader will be able to: Identify the different types of brainstem glioma in adults and their radiological features. Select the most accurate diagnostic test and propose options for treatment in patients suffering from brainstem gliomas.This article is available for continuing medical education credit at CME.TheOncologist.com Brainstem gliomas are uncommon in adults and account for only 1%–2% of intracranial gliomas. They represent a heterogeneous group of tumors that differ from those found in their pediatric counterparts. In adults, a low‐grade phenotype predominates, which is a feature that likely explains their better prognosis compared to that in children. Because biopsies are rarely performed, classifications based on the radiological aspect of magnetic resonance imaging results have been proposed to establish treatment strategies and to determine outcomes: (a) diffuse intrinsic low‐grade, (b) enhancing malignant glioma, (c) focal tectal gliomas, and (d) exophytic gliomas. Despite significant advances in neuroradiology techniques, a purely radiological classification remains imperfect in the absence of a histological diagnosis. Whereas a biopsy may often be reasonably avoided in the diffuse nonenhancing forms, obtaining histological proof seems necessary in many contrast‐enhanced brainstem lesions because of the wide variety of differential diagnoses in adults. Conventional radiotherapy is the standard treatment for diffuse intrinsic low‐grade brainstem gliomas in adults (the median survival is 5 years). In malignant brainstem gliomas, radiotherapy is the standard treatment. However, the possible benefit of combined radiotherapy and chemotherapy (temozolomide or other agents) has not been thoroughly evaluated in adults. The role of anti‐angiogenic therapies in brainstem gliomas remains to be defined. A better understanding of the biology of these tumors is of primary importance for identifying homogeneous subgroups and for improving therapy options and outcomes.